IL13RA2 and glioblastoma: In the first-in-human pilot study, twelve intracranial infusions (maximum dose 1 x 108) of IL13Rα2 CAR T cells were administrated into three patients with recurrent GBM, showing fair tolerance with delivery of CAR T cells and excellent antitumor response in two of the three treated patients.